Development of immune check point inhibitor loaded Lipiodol for local immunotherapy of HCC

Project: Research project

Project Details


The objective of this proposal is to develop a new local ICI immunotherapy using lipiodol for the treatment of HCC. ICB mediated immunotherapy has emerged as an effective and promising treatment for HCC. However, ICI immunotherapy needs to be localized for enhancing local ICI dose and preventing immune-related adverse events (IRAEs). A promising anti-PDL1 ICI molecule loaded lipiodol will serve as a new formulation achieving local immunotherapy to enhance current immune-therapeutic outcomes in HCC. We will optimize the synthesis protocols for ICI loaded lipiodol with bile acid, and ultimately validate that the ICI eluting lipiodol permits superior outcomes in an orthotropic rodent HCC model.
Effective start/end date3/1/202/28/23


  • Society of Interventional Oncology Inc. (Agmnt 03/03/20)


Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.